Bite Me Cancer is the newest member of the ATA Alliance for Patient Education and ThyCa is a founding member.
2014 ATA Research Grants Tatiana de Lourdes Fonseca, PhD – Rush University Medical Center, Chicago, IllinoisWhat is the Role of Type II Deiodinase (D2)-Mediated T3 Production in Liver and its Repercussion to Energy Expenditure?
Leo Kim, MD, PhD – Massachusetts Eye and Ear Infirmary, Boston, Massachusetts Animal Models of Acute and Chronic Thyroid Eye Disease
Peter Taylor MB, ChB - Cardiff University, United Kingdom The Impact of Maternal and Offspring Genetic Variants on Phenotypic Outcomes in the Controlled Antenatal Thyroid Screening Study (CATS).
W. Edward Visser, MD – Erasmus University Medical Center, Netherlands Thyroid Hormone and Aging
2014 ATA ThyCa GrantsElizabeth Grubbs, MD – The University of Texas M. D. Anderson Cancer Center, Houston, TexasFusion Oncogenes as Drivers of Medullary Thyroid Cancer
Jason Prescott, MD, PhD – Johns Hopkins School of Medicine, Baltimore, MarylandDevelopment of a High Throughput in vivo Screening System for Small Molecule Activators of Thyroid Differentiation: Identification and Targeting of New Molecular Pathways Involved Thyroid Cancer Progression
Brian Untch, MD - Memorial Sloan-Kettering Cancer Center, New York, New YorkMechanisms of Response and Resistance to Farnesyltransferase Inhibition in HRAS-driven Thyroid Tumors
2014 ATA Bite Me Cancer Grant Ramona Dadu, MD – The University of Texas M. D. Anderson Cancer Center, Houston, TexasImmune Markers in Medullary Thyroid Cancer (MTC) and Their Clinical Significance
2014 Second Year Grant Awardees:
ATA Research Grants Jennifer Morrison, MD, PhD - University of Colorado - Denver, Colorado TXNIP as a Regulator of Thyroid Cancer Aggressiveness
Joao Pedro Saar Werneck de Castro, PhD - University of Miami, Coral Gables, FloridaWhat is the Role Played by D2-mediated T3 Production in Skeletal Muscle?
Kevin Phillips, PhD - The Methodist Hospital Research Institute, Houston, Texas The Contribution of Cyp7a1 to the Cholesterol Lowering Actions of TR Agonists
ATA ThyCa Grants – Medullary Thyroid CancerNicole Chau, MD - Harvard Medical School, Boston, Massachusetts Overcoming Resistance to RET inhibitors in Medullary Thyroid Cancer
ATA ThyCa Grants – Thyroid CancerBrittany Bohinc, MD - Duke University Hospital, Durham, North CarolinaOverexpression of LGR4 and LGR5 in Human Thyroid Cancer Promotes Wnt/β-Catenin Signaling and is Associated with Tumor Aggressiveness
Jaroslaw Jendrzejewski, MD - Ohio State University, Columbus, Ohio Analysis of locus 14q13.3 in search of mutations predisposing to Papillary Thyroid Carcinoma (PTC)
###The American Thyroid Association (ATA) is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis and treatment of thyroid disorders and thyroid cancer. ATA is an international individual membership organization with over 1,400 members from 43 countries around the world.
Celebrating its 91st anniversary, ATA delivers its mission through several key endeavors: the publication of highly regarded monthly journals, THYROID, Clinical Thyroidology, VideoEndocrinology and Clinical Thyroidology for the Public; annual scientific meetings; biennial clinical and research symposia; research grant programs for young investigators, support of online professional, public and patient educational programs; and the development of guidelines for clinical management of thyroid disease.
More information about ATA is found at www.thyroid.org.